Current role of α-blockers in the treatment of benign prostatic hyperplasia

BJU International

Volumn 102, Issue SUPPL. 2, 2008, Pages 3-7

  Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

blocker; BOO; BPH; Doxazosin; LUTS; Prostate

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN; TERAZOSIN;

AGING; ANTIGEN DETECTION; ASTHENIA; BLADDER EMPTYING; BLADDER OBSTRUCTION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DISEASE ASSOCIATION; DISEASE COURSE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; MUSCLE CONTRACTION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEXUAL FUNCTION; SOMNOLENCE; SYMPTOMATOLOGY; URINE FLOW RATE; URINE RETENTION; DRUG DOSE TITRATION; DRUG FORMULATION; MICTURITION DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; CLINICAL TRIALS AS TOPIC; DOXAZOSIN; DRUG ADMINISTRATION ROUTES; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATISM;

EID: 53749101119     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08086.x     Document Type: Review

References (27)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984 132 : 474 9
2. Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol 2005 7 (Suppl. 4 S3 12
3. Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004 6 (Suppl. 9 S3 10
4. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005 7 (Suppl. 9 S3 14
5. Calais da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997 31 : 272 80
6. Roehrborn CG, Girman CJ, Rhodes T et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997 49 : 548 57
7. Slawin KM, Shariat S, Canto E. BPSA: a novel serum marker for benign prostatic hyperplasia. Rev Urol 2005 7 (Suppl. 8 S52 6
8. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999 53 : 581 9
9. Black L, Naslund MJ, Gilbert TD Jr., Davis EA, Ollendorf DA. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006 12 (Suppl. S99 110
10. 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996 29 : 129 44
11. 1A-adrenergic antagonist. Urology 1998 51 : 861 72
12. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α-adrenoceptor antagonists. BJU Int 2005 95 (Suppl. 4 29 36
13. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995 45 : 406 13
14. Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996 47 : 159 68
15. Lepor H, Kaplan SA, Klimberg I et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol 1997 157 : 525 30
16. Kaplan SA, D'Alisera PM. Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci 1998 53 : M201 6
17. Samli MM, Dincel C. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. Urol Int 2004 73 : 125 9
18. de Reijke TM, Klarskov P. Comparative efficacy of two α-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 2004 93 : 757 62
19. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003 61 : 119 26
20. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98
21. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996 48 : 406 15
22. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999 48 : 678 87
23. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000 38 : 400 9
24. Gratzke P, Kirby RS. [Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily]. MMW Fortschr Med 2000 142 : 40
25. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001 87 : 192 200
26. Roehrborn CG, Prajsner A, Kirby R, Andersen M, Quinn S, Mallen S. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia. Eur Urol 2005 48 : 445 52
27. Pompeo AC, Rosenblatt C, Bertero E et al. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. Int J Clin Pract 2006 60 : 1172 7